New combo tackles tough colorectal cancer in small trial

NCT ID NCT03828799

Completed Disease control Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two treatments (regorafenib and FOLFIRINOX) in 13 people with a type of advanced colorectal cancer that has a specific gene change (RAS mutation). The main goal was to see if the combination was safe and tolerable. The study also looked at how long the cancer stayed under control. This is not a cure, but aims to manage the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER

Contacts and locations

Show contact details

Locations

Centre Antoine Lacassagne

Nice, Alpes-Maritimes, 06189, France
Centre Cario - HPCA

Plérin, Finistère, 22190, France
Centre Georges-François Leclerc

Dijon, Côte d'Or, 21079, France
Institut du Cancer de Montpellier - Val d'Aurelle

Montpellier, 34298, France